Trial Profile

A Phase 4, Open-Label, Single-Center Study to Assess Pharmacokinetic Characteristics and Safety of Endari in Patients With Sickle Cell Disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glutamine (Primary)
Indications Sickle cell anaemia
Focus Pharmacokinetics
Sponsors Emmaus Medical

Most Recent Events

13 Dec 2022 Results(n=12) assessing Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia presented at the 64th American Society of Hematology Annual Meeting and Exposition
29 Jul 2022 Status changed from active, no longer recruiting to completed.
04 Mar 2022 According to an Emmaus Life Sciences, Inc media release, data from this trial will be presented as an e-poster at the 62nd Annual Meeting of the British Society for Haematology (BSH) 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com